Company Filing History:
Years Active: 1996-2002
Title: Katharina Fleischauer: Innovator in Cancer Research
Introduction
Katharina Fleischauer is a prominent inventor based in Milan, Italy. She has made significant contributions to the field of cancer research, particularly in the development of methods for stimulating cytolytic T cells. With a total of 3 patents to her name, her work is paving the way for innovative therapeutic approaches in oncology.
Latest Patents
Fleischauer's latest patents focus on methods for stimulating cytotoxic T lymphocytes (CTLs) using peptides derived from tumor rejection antigens. One of her notable inventions involves the identification of tumor rejection antigens from the precursor MAGE-3. These antigens, referred to as "T-RAS," bind to the MHC-class I molecule HLA-A2. The resulting complexes are instrumental in stimulating the production of cytolytic T cell clones that can effectively lyse presenting cells. These peptides and complexes hold promise for diagnostic and therapeutic applications, as well as for the generation of antibodies and cytolytic T cell clones.
Career Highlights
Fleischauer is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues her groundbreaking work. Her research is crucial in advancing our understanding of immune responses to tumors and developing new cancer therapies.
Collaborations
Throughout her career, Fleischauer has collaborated with esteemed colleagues such as Pierre Van Der Bruggen and Thierry R Boon-Falleur. These partnerships have further enriched her research and contributed to the advancement of cancer immunotherapy.
Conclusion
Katharina Fleischauer's innovative work in cancer research exemplifies the impact of scientific inquiry on therapeutic advancements. Her patents and collaborations are vital in the ongoing fight against cancer, showcasing the importance of innovation in medical science.